Valuation : Compass Therapeutics, Inc.

Market Cap 37Cr 32Cr 30Cr 27Cr 51Cr 3.53TCr 51Cr 356.77Cr 137.31Cr 1.79TCr 138.63Cr 135.6Cr 5.69TCr P/E 2026 *
-4.09x
P/E 2027 * -3.71x
Enterprise Value 22Cr 19Cr 18Cr 16Cr 30Cr 2.1TCr 31Cr 211.81Cr 82Cr 1.06TCr 82Cr 81Cr 3.38TCr EV / Sales 2026 *
-
EV / Sales 2027 * 10.5x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day-5.96%
1 week-13.50%
Current month-14.23%
1 month-7.66%
3 months+6.77%
6 months-63.20%
Current year-61.82%
1 week 2.04
Extreme 2.04
2.32
1 month 2.04
Extreme 2.04
2.55
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
29/04/26 Buy

Controller/Auditor

15,000 0.0083%
29/04/26 Buy

General Counsel

25,000 0.0139%
29/04/26 Free

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
-5.96%-13.50%-41.76%-10.48% 39Cr
-0.25%-0.96%+45.25%+102.76% 6.85TCr
-1.09%-6.20%+30.50%+76.56% 6.29TCr
-1.18%+0.47%-12.78%+384.69% 2.81TCr
-2.74%-6.31%+26.33%+13.50% 2.56TCr
-1.76%-6.30%-4.55%-19.75% 2.47TCr
-2.39%-5.19%+17.75%-20.95% 1.98TCr
-1.86%-2.22%+202.03%+353.89% 1.77TCr
-1.37%-4.51%-5.21%+528.34% 1.47TCr
-1.54%-2.88%+52.33%+159.75% 1.45TCr
Average -2.01%-3.15%+30.99%+156.83% 2.77TCr
Weighted average by Cap. -1.29%-2.20%+35.44%+138.86%

Financials

2026 *2027 *
Net sales - 2.24Cr 1.93Cr 1.82Cr 1.66Cr 3.09Cr 214.1Cr 3.12Cr 22Cr 8.33Cr 108.59Cr 8.41Cr 8.23Cr 344.92Cr
Net income -9.4Cr -8.09Cr -7.63Cr -6.95Cr -13Cr -899.12Cr -13Cr -91Cr -35Cr -456.05Cr -35Cr -35Cr -1.45TCr -11Cr -9.45Cr -8.91Cr -8.12Cr -15Cr -1.05TCr -15Cr -106.14Cr -41Cr -532.6Cr -41Cr -40Cr -1.69TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.43TCr -21Cr -144.96Cr -56Cr -727.41Cr -56Cr -55Cr -2.31TCr -13Cr -11Cr -11Cr -9.83Cr -18Cr -1.27TCr -19Cr -128.53Cr -49Cr -644.97Cr -50Cr -49Cr -2.05TCr
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
10/26/10 $2.050 -5.96% 25,38,843
09/26/09 $2.180 -1.36% 26,14,911
08/26/08 $2.210 -7.14% 24,28,040
04/26/04 $2.380 +0.42% 25,48,324
03/26/03 $2.370 -2.47% 25,59,952
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.050USD
Average target price
8.917USD
Spread / Average Target
+334.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!